# Safety Study of AMG 228 to Treat Solid Tumors

> **NCT02437916** · PHASE1 · TERMINATED · sponsor: **Amgen** · enrollment: 30 (actual)

## Conditions studied

- Advanced Malignancy
- Advanced Solid Tumors
- Cancer
- Oncology
- Oncology Patients
- Tumors
- Melanoma
- Non-small Cell Lung Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Transitional Cell Carinoma of Bladder
- Colorectal Cancer

## Interventions

- **DRUG:** AMG 228

## Key facts

- **NCT ID:** NCT02437916
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-04-21
- **Primary completion:** 2016-12-12
- **Final completion:** 2016-12-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-11-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02437916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02437916, "Safety Study of AMG 228 to Treat Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02437916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*